Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12354632 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL12203387 | 1.00 | ALDH1A1 (0.35) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL22821849 | 0.86 | — | — | |
| SCHEMBL31675120 | 0.78 | ALDH1A1 (0.33) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL1470730 | 0.78 | — | — | |
| SCHEMBL1991395 | 0.76 | ALDH1A1 (0.37) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL12868464 | 0.76 | ALDH1A1 (0.37) | ALDH1A1TSHRMAPK1 | |
| SCHEMBL24310407 | 0.75 | — | — | |
| SCHEMBL8405227 | 0.75 | — | — | |
| SCHEMBL16977337 | 0.75 | ALDH1A1 (0.32) | ALDH1A1TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240074301-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-29 | — | — | US | disclosed |
| US-11826351-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | LOXO ONCOLOGY, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| US-20230357296-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-09 | — | — | US | disclosed |
| US-20230348509-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230320188-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230284517-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-07 | — | — | US | disclosed |
| US-7790770-B2 | Heterocyclic CETP inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-02-25 | — | — | US | disclosed |
| US-7632837-B2 | Bicyclic heterocycles as cannabinoid-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-15 | — | — | US | disclosed |
| US-20090286188-A1 | Patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-7595299-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2009-09-29 | — | — | US | disclosed |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | MERCK SHARP & DOHME LLC | 2009-02-05 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TSHR 2250/4885MAPK1 3848/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | ALDH1A1 164/4885TSHR 481/4885MAPK1 2215/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | ALDH1A1 2353/4885TSHR 2250/4885MAPK1 3848/4885 |
| US-20230284517-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, OCIAD2, OCIAD1 | ALDH1A1 838/4885TSHR 836/4885MAPK1 3547/4885 |
| US-20230320188-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OCIAD1, OCIAD2, MLX | ALDH1A1 1799/4885TSHR 1013/4885MAPK1 595/4885 |
| US-20230357296-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OPRD1, OXER1, LBR | ALDH1A1 1046/4885TSHR 661/4885MAPK1 721/4885 |
| US-20090036503-A1 | Triazole Derivatives as Inhibitors of 11-Beta-Hydroxysteroid Dehydrogenase-1 | HSD11B1, HSD17B1, HSD3B1 | ALDH1A1 145/4885TSHR 2310/4885MAPK1 465/4885 |
| US-20240074301-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, OCIAD2, OSBP | ALDH1A1 658/4885TSHR 1042/4885MAPK1 3593/4885 |
| US-11826351-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | ALDH1A1 4454/4885TSHR 3509/4885MAPK1 320/4885 |
| US-20230372298-A1 | COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, ABL1, LCK | ALDH1A1 4454/4885TSHR 3509/4885MAPK1 320/4885 |
| US-20230348509-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | MLX, OCIAD1, LBR | ALDH1A1 1681/4885TSHR 923/4885MAPK1 2234/4885 |
| US-20230365606-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | OXER1, OPRD1, OXSR1 | ALDH1A1 728/4885TSHR 159/4885MAPK1 1114/4885 |
| US-20100048612-A1 | BICYCLIC HETEROCYCLES AS CANNABINOID-1 RECEPTOR MODULATORS | CNR1, CNR2, GPR18 | ALDH1A1 1341/4885TSHR 565/4885MAPK1 1314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.